Belite Bio (BLTE) Long-Term Investments (2024 - 2025)
Belite Bio (BLTE) posted quarterly Long-Term Investments of $280.2 million for Q4 2025, up 146.9% year-over-year from $113.5 million in Q4 2024, and up 146.9% quarter-over-quarter from $113.5 million in Q4 2024.
Belite Bio (BLTE) Long-Term Investments (2024 - 2025) Analysis & Trends
Belite Bio's Long-Term Investments history runs 2 years deep, the most recent figure standing at $280.2 million for Q4 2025.
- In Q4 2025, Long-Term Investments rose 146.9% year-over-year to $280.2 million; the TTM figure through Dec 2025 stood at $280.2 million (up 146.9% YoY), while the FY2025 annual figure was $280.2 million, up 146.9% from the prior year.
- Long-Term Investments for Q4 2025 stood at $280.2 million, up from $113.5 million in the prior quarter.
- The five-year high for Long-Term Investments was $280.2 million in Q4 2025, with the low at $113.5 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Belite Bio | 6.40 Bn | 6.40 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 280.17 Mn |
| Dec 31, 2024 | 113.47 Mn |